NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
02/21/2024
Back to search
Official data from USPTO
SERACARE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
SERACARE
ST13
US500000077832375Class
1, 5, 42
Filing
77832375
Registration
4451588
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
70
Latest update
02/21/2024
Trademark type
Word
Nice classes
1, 5, 42
Filing date
09/22/2009
Registration date
12/17/2013
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/21/2024
Last transaction
02/21/2024
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
09/26/2001
First use in commerce
09/26/2001
Drawing code
4
Owner type
03
Owner location
MILFORD, MA
Examiner
JUN,WON KYUNG WENDY
Law office
L30
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
LGC CLINICAL DIAGNOSTICS, INC.
SERACARE LIFE SCIENCES, INC.
Representatives
Mainak H. Mehta Procopio, Cory, Hargreaves & Savitch LLP
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Diagnostic chemicalsreagents or preparations for scientificresearch or manufacturing use in chemicalpharmaceutical and biotechnology industries; Diagnostic reagents for clinicalmedical laboratory or manufacturing use in chemicalpharmaceutical and biotechnology industries; Diagnostic reagents for in vitro use in biochemistryclinical chemistrymicrobiology; Reagents and toolsanimal serumsbovine serum albuminhuman blood productsplasmaserumcellshuman serum albuminchromogenic substratesall for research purposes or manufacturing use in chemicalpharmaceutical and biotechnology industries; Chemical reagents other than for medical or veterinary purposes; Chemical preparations for scientific purposes; Chemical ingredients for use as exipients or diluents in the manufacture of pharmaceuticals; Chemical reagents for reference controlgenetic testing controls and controls for the testing of human seruminfectious disease antibodies and antigensviral nucleic acidsall for industrial use and not for medical purposes; Chemical solutions in the nature of quality control standard solutions for testing human seruminfectious disease antibodies and antigenshuman geneticsviral nucleic acidsall for industrial use and not for medical purposes; Chemical control serum for scientific or research use in the nature of quality controls for infectious disease and genetic testing; Biochemical control serum for scientific or research use in the nature of quality controls for infectious disease and genetic testing; Biochemical standard serum for scientific or research use; Quality control standard solutions and quality control materials for testing and calibrating medical apparatus and reagents for scientific and research purposes and for clinical or medical laboratory use; Standard serumcontrol serumbiochemical standard serumbiochemical control serum for scientific and research purposes and for clinical or medical laboratory use
Class 5
Diagnostic reagents for medical and veterinary use; Clinical medical reagents; Diagnostic chemicalsreagents or preparations for medical and veterinary use; Chemical reagents for medical and veterinary use; Chemical reagents for pharmaceutical purposes and use in the pharmaceutical industrychemical reagents for use as diluents and excipients; Testing reagents for medical or clinical use; Genetic testing controls for the testing of human seruminfectious disease antibodies and antigensviral nucleic acidsmedical diagnostic reagents and assays; Chemical reference materialsquality controls and panels in the nature of human compounds for medical or veterinary use; Chemical reference specimensserologicalviralgenetic and nucleic acid reference specimens in the nature of human seruminfectious disease antibodies and antigens for medical or veterinary use
Class 42
Custom design and development of chemical reagents and biochemical assays; Providing reagent sample testing for others in the fields ofscience and research related thereto; Research support services in the nature of assay development and validationproduct developmentreport generationall in the fields of virologyimmunologicalbiological and biochemical research
Publications
History of USPTO decisions and trademark events.
70 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
02/21/2024
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
02/21/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/21/2024
E89R
TEAS SECTION 8 & 9 RECEIVED
08/26/2023
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
12/17/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
10/05/2022
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
08/10/2020
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
08/10/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/10/2020
E815
TEAS SECTION 8 & 15 RECEIVED
06/12/2020
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
12/17/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
12/17/2013
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/13/2013
REGV
LAW OFFICE REGISTRATION REVIEW COMPLETED
11/12/2013
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/11/2013
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/06/2013
IUAF
USE AMENDMENT FILED
10/24/2013
EISU
TEAS STATEMENT OF USE RECEIVED
10/24/2013
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/02/2013
EX3G
SOU EXTENSION 3 GRANTED
05/01/2013
EXT3
SOU EXTENSION 3 FILED
04/25/2013
EEXT
SOU TEAS EXTENSION RECEIVED
04/25/2013
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/31/2012
EX2G
SOU EXTENSION 2 GRANTED
10/30/2012
EXT2
SOU EXTENSION 2 FILED
10/25/2012
EEXT
SOU TEAS EXTENSION RECEIVED
10/25/2012
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/17/2012
EX1G
SOU EXTENSION 1 GRANTED
05/16/2012
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/16/2012
EXT1
SOU EXTENSION 1 FILED
04/25/2012
EEXT
SOU TEAS EXTENSION RECEIVED
04/25/2012
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
10/25/2011
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/30/2011
PUBO
PUBLISHED FOR OPPOSITION
08/30/2011
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
07/26/2011
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/20/2011
XAEC
EXAMINER'S AMENDMENT ENTERED
07/19/2011
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/18/2011
GNEA
EXAMINERS AMENDMENT E-MAILED
07/18/2011
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/18/2011
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/23/2011
GNRT
NON-FINAL ACTION E-MAILED
03/23/2011
CNRT
NON-FINAL ACTION WRITTEN
03/23/2011
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
03/15/2011
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
02/28/2011
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/17/2011
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/17/2011
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/03/2011
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/03/2011
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/01/2011
CEPE
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED
02/01/2011
GEAN
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
01/31/2011
GEAP
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
01/31/2011
CPEA
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
01/31/2011
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/13/2010
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
07/29/2010
GNFR
FINAL REFUSAL E-MAILED
07/29/2010
CNFR
FINAL REFUSAL WRITTEN
07/29/2010
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/09/2010
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/09/2010
ALIE
ASSIGNED TO LIE
07/09/2010
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/21/2010
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/19/2009
GNRT
NON-FINAL ACTION E-MAILED
12/19/2009
CNRT
NON-FINAL ACTION WRITTEN
12/19/2009
DOCK
ASSIGNED TO EXAMINER
12/18/2009
MPMK
NOTICE OF PSEUDO MARK MAILED
09/26/2009
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/25/2009
NWAP
NEW APPLICATION ENTERED
09/25/2009
Continuous trademark protection
Get notified about every new filing that threatens SERACARE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.